Instil Bio (TIL) announced the addition of John Maraganore, Ph.D., to the Board of Directors of Axion Bio, Instil’s wholly-owned subsidiary dedicated to the development of AXN-2510, a potentially best-in-class PD-L1xVEGF bispecific antibody for solid tumors prioritizing front-line non-small cell lung cancer
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TIL: